Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.31 |
| ▸ | PDE4A known ✓ | P27815 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | HBB | P68871 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447715 | 1.00 | KDM4E (0.34) | KDM4EMAPTALOX15ALDH1A1TSHR | |
| SCHEMBL1392763 | 0.93 | ALDH1A1 (0.37) | KDM4EMAPTALOX15ALDH1A1LMNA | |
| SCHEMBL4455864 | 0.89 | ALOX15 (0.42) | KDM4EMAPTALOX15ALDH1A1TSHR | |
| SCHEMBL29463334 | 0.87 | KMT2A (0.44) | KDM4EALDH1A1SMN1; SMN2MEN1KMT2A | |
| Water SCHEMBL9983319 | 0.87 | MAPT (0.40) | KDM4EMAPTALOX15ALDH1A1TSHR | |
| Water SCHEMBL15641760 | 0.87 | PTGS1 (0.36) | MAPTALOX15ALDH1A1LMNAMAPK1 | |
| SCHEMBL2403909 | 0.87 | — | — | |
| SCHEMBL789961 | 0.87 | PTGS1 (0.39) | KDM4EMAPTALOX15ALDH1A1LMNA | |
| SCHEMBL63679 | 0.87 | PTGS1 (0.39) | KDM4EMAPTALOX15ALDH1A1LMNA | |
| SCHEMBL14414885 | 0.87 | PTGS1 (0.39) | KDM4EMAPTALOX15ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034242-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | NOF CORPORATION (JP) | 2026-02-05 | — | — | US | disclosed |
| US-12392787-B2 | Method for quantifying the amount of cholesterol in high-density lipoprotein 3 | DENKA COMPANY LIMITED (JP) | 2025-08-19 | — | — | US | disclosed |
| EP-4556000-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | NOF Corporation (JP) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024014512-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | 日油株式会社 | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034242-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | SREBF1, FASN, ACSS2 | PTGS1 2153/4885PDE4A 3945/4885KDM4E 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.